Dysadherin Antibody (G-6): sc-390412

Dysadherin Antibody (G-6) is a mouse monoclonal IgG1 antibody that detects Dysadherin in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Dysadherin, also known as FXYD domain-containing ion transport regulator 5, plays a critical role in cancer biology as a cell membrane glycoprotein associated with tumor progression. Dysadherin down-regulates E-cadherin expression, which is essential for maintaining cell-cell adhesion in epithelial tissues. This down-regulation occurs through a posttranscriptional mechanism, leading to decreased intercellular adhesion and facilitating cancer cell metastasis. Dysadherin is predominantly located in the cell membrane, where Dysadherin′s presence is crucial for regulating cellular interactions and signaling pathways that influence tumor behavior. Dysadherin is expressed in various tissues, including the spleen, lung, skeletal muscle, and testis, and is mapped to human chromosome 19q13.12. Anti-Dysadherin antibody (G-6) serves as an invaluable tool for researchers investigating cancer metastasis mechanisms and cell adhesion roles in tumor progression.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Dysadherin Antibody (G-6) References:

1. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.  |  Shimamura, T., et al. 2003. J Clin Oncol. 21: 659-67. PMID: 12586803
2. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.  |  Tsuiji, H., et al. 2003. Glycobiology. 13: 521-7. PMID: 12672699
3. Clinical significance of dysadherin expression in gastric cancer patients.  |  Shimada, Y., et al. 2004. Clin Cancer Res. 10: 2818-23. PMID: 15102690
4. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.  |  Nakanishi, Y., et al. 2004. Appl Immunohistochem Mol Morphol. 12: 323-8. PMID: 15536331
5. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.  |  Wu, D., et al. 2004. Pathol Oncol Res. 10: 212-8. PMID: 15619642
6. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.  |  Kyzas, PA., et al. 2006. Am J Surg Pathol. 30: 185-93. PMID: 16434892
7. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.  |  Nam, JS., et al. 2006. Cancer Res. 66: 7176-84. PMID: 16849564
8. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.  |  Batistatou, A., et al. 2007. Br J Cancer. 96: 1404-8. PMID: 17437014
9. Adhesion molecules in cancer of the head and neck: role of dysadherin.  |  Giotakis, I., et al. 2011. J BUON. 16: 609-12. PMID: 22331710
10. Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells.  |  Jiang, N., et al. 2015. Mol Med Rep. 12: 7239-46. PMID: 26458963

The preferred Dysadherin antibody is Dysadherin Antibody (D-10): sc-377163.